arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

MANNKIND CORP

MNKD
$4.10 ▲ +0.21 (+5.53%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
84 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Bullish
auto_awesome

Analytical Summary

MANNKIND CORP shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.3B
Dividend Yield
Revenue Growth 15.1%
Op. Margin -1.8%
ROIC -0.7%
FCF / Share $-0.02
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -5.38
info Valuation on last close. End-of-day price, Aug 7, 2026.

84-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$90.17M
↑ +15.1%
Net Income Profit after all expenses
$-16.62M
↓ -4.2%
Operating Margin Operating profit as % of sales
-1.8%
↑ +73.1% 59th
FCF / Share Free cash flow per share
$-0.02
↓ -6.3%
Long-Term Debt Long-term obligations
$318.72M
↓ -10.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
45
Returns
33
Financial Health
82
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 35 years · 84 quarters